Agenus (FRA:AJ8) Cyclically Adjusted PB Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AJ8 Agenus Inc FRA:AJ8
48 GF Score
Price €6.10
GF Value €3.22
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus  (FRA:AJ8) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Agenus Cyclically Adjusted PB Ratio Related Terms


Agenus Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Agenus's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus Cyclically Adjusted PB Ratio Chart

Agenus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Agenus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:AJ8 vs FULC, IRD, TTRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PB Ratio falls into.


FRA:AJ8
48GF Score
Agenus Inc FRA:AJ8
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Agenus's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Agenus's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-3.861/333.9520*333.9520
=-3.861

Current CPI (Jun. 2026) = 333.9520.

Agenus Quarterly Data

Book Value per Share CPI Adj_Book
201609 -4.303 241.428 -5.952
201612 -8.449 241.432 -11.687
201703 1.687 243.801 2.311
201706 -3.124 244.955 -4.259
201709 -8.680 246.819 -11.744
201712 -12.599 246.524 -17.067
201803 -17.807 249.554 -23.829
201806 -17.352 251.989 -22.996
201809 -18.885 252.439 -24.983
201812 -25.266 251.233 -33.585
201903 -15.317 254.202 -20.122
201906 -20.275 256.143 -26.434
201909 -26.400 256.759 -34.337
201912 -29.433 256.974 -38.250
202003 -21.716 258.115 -28.096
202006 -22.650 257.797 -29.341
202009 -17.817 260.280 -22.860
202012 -17.075 260.474 -21.892
202103 -14.625 264.877 -18.439
202106 -18.211 271.696 -22.384
202109 2.875 274.310 3.500
202112 2.373 278.802 2.842
202203 1.070 287.504 1.243
202206 0.229 296.311 0.258
202209 -1.396 296.808 -1.571
202212 -3.786 296.797 -4.260
202303 -3.200 301.836 -3.540
202306 -4.681 305.109 -5.124
202309 -6.344 307.789 -6.883
202312 -7.456 306.746 -8.117
202403 -8.827 312.332 -9.438
202406 -10.611 314.175 -11.279
202409 -12.146 315.301 -12.864
202412 -13.188 315.605 -13.955
202503 -11.904 319.799 -12.431
202506 -10.247 322.561 -10.609
202509 -7.118 324.800 -7.319
202512 -6.555 324.054 -6.755
202603 -4.967 330.213 -5.023
202606 -3.861 333.952 -3.861

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Agenus (FRA:AJ8) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of €6.10 is trading 89.4% above its estimated GF Value™ of €3.22. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for FRA:AJ8:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €3.22 vs. price of €6.10 (89.4% above fair value)
  • GF Score™: 48/100 with 12 warning signs

No single metric tells the full story. See the FRA:AJ8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agenus Business Description

Other Exchanges AGEN:USA
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
48GF Score

Get the complete analysis for FRA:AJ8

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.10
Price
€3.22
GF Value